Research Report University Hospital for clinical assessment GO28141

Abstract

A Phase 3 Study Comparing GDC-0973 (cobimetinib), a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients with Metastatic Melanoma

Keywords

• Metastatic Melanoma
• GDC-0973 (cobimetinib)